Digestive Diseases and Sciences

, Volume 43, Issue 12, pp 2573–2576 | Cite as

Regression of Hepatic Fibrosis in Hepatitis C with Long-Term Interferon Treatment

  • Jean-Francois Dufour
  • Ronald Delellis
  • Marshall M. Kaplan
Article

Abstract

Cirrhosis occurs in 20-50% of patients with hepatitis C and is thought to be irreversible. We describe two patients with cirrhosis secondary to hepatitis C in whom the extensive fibrosis and cirrhosis appeared to regress in response to treatment with interferon-α (IFN-α). Both patients were in the early stages of cirrhosis, class A in the Child-Pugh classification, total score 5 for each patient. Both responded fully to IFN-α and had normalization of all liver function tests and disappearance of hepatitis C viral RNA. Liver biopsies, performed before and after treatment, were coded unpaired by patient, combined with 21 liver biopsies from eight other patients with chronic hepatitis, and read independently by two pathologists using the Knodell scoring system. Knodell scores decreased from 14 to 3.5 and from 13.5 to 4 in these two patients. Cirrhosis and extensive fibrosis, present at baseline, were not present on follow-up liver biopsies, which were of sufficient size to reduce the likelihood of sampling error. We conclude that hepatic fibrosis and clinically early cirrhosis may be reversible in some patients with hepatitis C who respond to treatment with IFN-α.

FIBROSIS HEPATITIS C INTERFERON-α 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463- 1466, 1995Google Scholar
  2. 2.
    Poynard T, Bedossa P, Chevallier M: A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457- 1462, 1995Google Scholar
  3. 3.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for asse ssing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431- 435, 1981Google Scholar
  4. 4.
    Powell LW, Kerr JFR: Reversal of cirrhosis in idiopathic hemochromatosis following long-term intensive venesection therapy. Australas Ann Med 2:54, 1970Google Scholar
  5. 5.
    Falkmer S, Samuelson G, Sjolin S: Penicillamine-induced normalization of clinical signs and normal liver morphology and histochemistry in a case of Wilson's disease. Pediatrics 45:260 - 268, 1970Google Scholar
  6. 6.
    Kaplan MM, De Lellis RA, Wolfe HJ: Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 126:682- 688, 1997Google Scholar
  7. 7.
    Dufour J-F, De Lellis RA, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127:981- 985, 1997Google Scholar
  8. 8.
    Crawford JM: The liver and the biliary tract. InPathologic Basis of Disease. RS Cotran, V Kumar, SL Robbins (eds). Philadelphia, WB Saunders Company, 1994, pp 831- 896Google Scholar
  9. 9.
    Hall P, Dela M: Alcoholic liver disease. InPathology of the Liver, 2nd ed. RNM McSween, P Anthony, PJ Scheuer, (eds). Edinburgh, Churchill Livingstone, 1987, p 291Google Scholar
  10. 10.
    Castilla A, Prieto J, Fausto N: Transforming growth factors β1 and α in chronic liver disease: Effects of interferon alpha therapy: N Engl J Med 324:933- 940, 1991Google Scholar
  11. 11.
    Mallat A, Preaux A-M, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P: Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 21:1003- 1010, 1995Google Scholar
  12. 12.
    Berman B, Duncan MR: Short-term keloid treatment in vivo with human interferon alpha-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycos-aminoglycan, and collagenase production in vitro. J Am Acad Dermatol 21:694 - 702, 1989Google Scholar
  13. 13.
    Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J: Randomised trial of lymphoblastoid interferon a in chronic hepatitis C. J Hepatol 17:390 - 396, 1993Google Scholar
  14. 14.
    Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud J-A: Interferon α-2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation. Hepatology 18:1344 - 1349, 1993Google Scholar
  15. 15.
    Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, Fusamoto H, Kamada T: Improvement of liver fi brosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22:135- 142, 1995Google Scholar
  16. 16.
    Ziol M, Tran Van Nhieu J, Roudot-Thoraval F, Métreau J-M, Deugnier Y, Dhumeaux D, Zafrani E: A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C. J Hepatol 25:833- 841, 1996Google Scholar
  17. 17.
    Abdi W, Millan JC, Mezey E: Sampling variability on percutaneous liver biopsy. Arch Intern Med 39:667- 669, 1979Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Jean-Francois Dufour
  • Ronald Delellis
  • Marshall M. Kaplan

There are no affiliations available

Personalised recommendations